LUMOSA THERAPEUTICS CO., LTD.

Lumosa Therapeutics announces Phase II trial results for LT3001 in China, showing robust safety and preliminary efficacy in acute ischemic stroke patients. No symptomatic intracranial hemorrhages were observed, and a promising proportion of patients achieved 0-1 mRS scores at Day 90. The results support further development and global licensing negotiations.